RNA interference-based therapeutics for inherited long QT syndrome (Review)

Li,Guoliang; Ma,Shuting; Sun,Chaofeng

doi:10.3892/etm.2015.2573

RNA interference-based therapeutics for inherited long QT syndrome (Review)

Authors:
- Guoliang Li
- Shuting Ma
- Chaofeng Sun
View Affiliations

Affiliations: Department of Cardiovascular Medicine, The First Affiliated Hospital of Xi'an Jiaotong University College of Medicine, Xi'an, Shaanxi 710061, P.R. China
Published online on: June 12, 2015 https://doi.org/10.3892/etm.2015.2573
Pages: 395-400

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Inherited long QT syndrome (LQTS) is an electrical heart disorder that manifests with syncope, seizures, and increased risk of torsades de pointes and sudden cardiac death. Dominant‑negative current suppression is a mechanism by which pathogenic proteins disrupt the function of ion channels in inherited LQTS. However, current approaches for the management of inherited LQTS are inadequate. RNA interference (RNAi) is a powerful technique that is able to suppress or silence the expression of mutant genes. RNAi may be harnessed to knock out mRNAs that code for toxic proteins, and has been increasingly recognized as a potential therapeutic intervention for a range of conditions. The present study reviews the literature for RNAi‑based therapeutics in the treatment of inherited LQTS. Furthermore, this review discusses the combined use of RNAi with the emerging technology of induced pluripotent stem cells for the treatment of inherited LQTS. In addition, key challenges that must be overcome prior to RNAi‑based therapies becoming clinically applicable are addressed. In summary, RNAi‑based therapy is potentially a powerful therapeutic intervention, although a number of difficulties remain unresolved.

View Figures

View References

1	Schwartz PJ, Stramba-Badiale M, Crotti L, et al: Prevalence of the congenital long-QT syndrome. Circulation. 120:1761–1767. 2009. View Article : Google Scholar : PubMed/NCBI
2	Tester DJ and Ackerman MJ: Genetic testing for potentially lethal, highly treatable inherited cardiomyopathies/channelopathies in clinical practice. Circulation. 123:1021–1037. 2011. View Article : Google Scholar : PubMed/NCBI
3	Hedley PL, Jørgensen P, Schlamowitz S, et al: The genetic basis of long QT and short QT syndromes: A mutation update. Hum Mutat. 30:1486–1511. 2009. View Article : Google Scholar : PubMed/NCBI
4	Yang Y, Yang Y, Liang B, et al: Identification of a Kir3.4 mutation in congenital long QT syndrome. Am J Hum Genet. 86:872–880. 2010. View Article : Google Scholar : PubMed/NCBI
5	Cerrone M, Napolitano C and Priori SG: Genetics of ion-channel disorders. Curr Opin Cardiol. 27:242–252. 2012. View Article : Google Scholar : PubMed/NCBI
6	Tester DJ, Will ML, Haglund CM and Ackerman MJ: Compendium of cardiac channel mutations in 541 consecutive unrelated patients referred for long QT syndrome genetic testing. Heart Rhythm. 2:507–517. 2005. View Article : Google Scholar : PubMed/NCBI
7	Schwartz PJ, Crotti L and Insolia R: Long-QT syndrome: From genetics to management. Circ Arrhythm Electrophysiol. 5:868–877. 2012. View Article : Google Scholar : PubMed/NCBI
8	Zarzoso M and Noujaim SF: Mission possible: RNA interference rescues the hERG current. Heart Rhythm. 10:137–138. 2013. View Article : Google Scholar : PubMed/NCBI
9	Grimm D and Kay MA: RNAi and gene therapy: A mutual attraction. Hematology (Am Soc Hematol Educ Program). 473–481. 2007. View Article : Google Scholar : PubMed/NCBI
10	Seyhan AA: RNAi: A potential new class of therapeutic for human genetic disease. Hum Genet. 130:583–605. 2011. View Article : Google Scholar : PubMed/NCBI
11	Zhang A, Sun C, Zhang L, et al: L539 fs/47, a truncated mutation of human ether-a-go-go-related gene (hERG), decreases hERG ion channel currents in HEK 293 cells. Clin Exp Pharmacol Physiol. 40:28–36. 2013. View Article : Google Scholar : PubMed/NCBI
12	Delisle BP, Anson BD, Rajamani S and January CT: Biology of cardiac arrhythmias: Ion channel protein trafficking. Circ Res. 94:1418–1428. 2004. View Article : Google Scholar : PubMed/NCBI
13	Thomas D, Kiehn J, Katus HA and Karle CA: Defective protein trafficking in hERG-associated hereditary long QT syndrome (LQT2): Molecular mechanisms and restoration of intracellular protein processing. Cardiovasc Res. 60:235–241. 2003. View Article : Google Scholar : PubMed/NCBI
14	Anderson CL, Delisle BP, Anson BD, et al: Most LQT2 mutations reduce Kv11.1 (hERG) current by a class 2 (trafficking-deficient) mechanism. Circulation. 113:365–373. 2006. View Article : Google Scholar : PubMed/NCBI
15	Castanotto D and Rossi JJ: The promises and pitfalls of RNA-interference-based therapeutics. Nature. 457:426–433. 2009. View Article : Google Scholar : PubMed/NCBI
16	Petrocca F and Lieberman J: Promise and challenge of RNA interference-based therapy for cancer. J Clin Oncol. 29:747–754. 2011. View Article : Google Scholar : PubMed/NCBI
17	Davidson BL and McCray PB Jr: Current prospects for RNA interference-based therapies. Nat Rev Genet. 12:329–340. 2011. View Article : Google Scholar : PubMed/NCBI
18	Suckau L, Fechner H, Chemaly E, et al: Long-term cardiac-targeted RNA interference for the treatment of heart failure restores cardiac function and reduces pathological hypertrophy. Circulation. 119:1241–1252. 2009. View Article : Google Scholar : PubMed/NCBI
19	Poller W, Tank J, Skurk C and Gast M: Cardiovascular RNA interference therapy: The broadening tool and target spectrum. Circ Res. 113:588–602. 2013. View Article : Google Scholar : PubMed/NCBI
20	Lu X, Yang X, Huang X, et al: RNA interference targeting E637K mutation rescues hERG channel currents and restores its kinetic properties. Heart Rhythm. 10:128–136. 2013. View Article : Google Scholar : PubMed/NCBI
21	Sanguinetti MC and Tristani-Firouzi M: hERG potassium channels and cardiac arrhythmia. Nature. 440:463–469. 2006. View Article : Google Scholar : PubMed/NCBI
22	Iwai C, Li P, Kurata Y, et al: Hsp90 prevents interaction between CHIP and HERG proteins to facilitate maturation of wild-type and mutant HERG proteins. Cardiovasc Res. 100:520–528. 2013. View Article : Google Scholar : PubMed/NCBI
23	Curran ME, Splawski I, Timothy KW, Vincent GM, Green ED and Keating MT: A molecular-basis for cardiac-arrhythmia: HERG mutations cause long QT syndrome. Cell. 80:795–803. 1995. View Article : Google Scholar : PubMed/NCBI
24	Gong Q, Zhang L, Vincent GM, Horne BD and Zhou Z: Nonsense mutations in hERG cause a decrease in mutant mRNA transcripts by nonsense-mediated mRNA decay in human long-QT syndrome. Circulation. 116:17–24. 2007. View Article : Google Scholar : PubMed/NCBI
25	Ficker E, Dennis AT, Obejero-Paz CA, Castaldo P, Taglialatela M and Brown AM: Retention in the endoplasmic reticulum as a mechanism of dominant-negative current suppression in human long QT syndrome. J Mol Cell Cardiol. 32:2327–2337. 2000. View Article : Google Scholar : PubMed/NCBI
26	Poller W, Hajjar R, Schultheiss HP and Fechner H: Cardiac-targeted delivery of regulatory RNA molecules and genes for the treatment of heart failure. Cardiovasc Res. 86:353–364. 2010. View Article : Google Scholar : PubMed/NCBI
27	Denovan-Wright EM and Davidson BL: RNAi: A potential therapy for the dominantly inherited nucleotide repeat diseases. Gene Ther. 13:525–531. 2006. View Article : Google Scholar : PubMed/NCBI
28	Judge AD, Robbins M, Tavakoli I, et al: Confirming the RNAi-mediated mechanism of action of siRNA-based cancer therapeutics in mice. J Clin Invest. 119:661–673. 2009. View Article : Google Scholar : PubMed/NCBI
29	Fitzgerald K, Frank-Kamenetsky M, Shulga-Morskaya S, et al: Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: A randomised, single-blind, placebo-controlled, phase 1 trial. Lancet. 383:60–68. 2014. View Article : Google Scholar : PubMed/NCBI
30	Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE and Mello CC: Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature. 391:806–811. 1998. View Article : Google Scholar : PubMed/NCBI
31	Bumcrot D, Manoharan M, Koteliansky V and Sah DWY: RNAi therapeutics: A potential new class of pharmaceutical drugs. Nat Chem Biol. 2:711–719. 2006. View Article : Google Scholar : PubMed/NCBI
32	Almaça J, Faria D, Sousa M, et al: High-content siRNA screen reveals global ENaC regulators and potential cystic fibrosis therapy targets. Cell. 154:1390–1400. 2013. View Article : Google Scholar : PubMed/NCBI
33	Kanasty R, Dorkin JR, Vegas A and Anderson D: Delivery materials for siRNA therapeutics. Nat Mater. 12:967–977. 2013. View Article : Google Scholar : PubMed/NCBI
34	Coelho T, Adams D, Silva A, et al: Safety and efficacy of RNAi therapy for transthyretin amyloidosis. N Engl J Med. 369:819–829. 2013. View Article : Google Scholar : PubMed/NCBI
35	Wallace LM, Garwick SE and Harper SQ: RNAi therapy for dominant muscular dystrophies and other myopathies. Muscle Gene Ther. 99–115. 2010. View Article : Google Scholar
36	Hayashi K, Shimizu M, Ino H, et al: Characterization of a novel missense mutation E637K in the pore-S6 loop of HERG in a patient with long QT syndrome. Cardiovasc Res. 54:67–76. 2002. View Article : Google Scholar : PubMed/NCBI
37	Matsa E, Dixon JE, Medway C, et al: Allele-specific RNA interference rescues the long-QT syndrome phenotype in human-induced pluripotency stem cell cardiomyocyte. Eur Heart J. 35:1078–1087. 2014. View Article : Google Scholar : PubMed/NCBI
38	Meng S and Tian Y: Cell reprogramming: The revolutionary breakthrough in regenerative medicine research-written on the occasion of the 2012 nobel prize in physiology or medicine issued. Prog Biochem Biophys. 39:1061–1065. 2012. View Article : Google Scholar
39	Takahashi K and Yamanaka S: Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell. 126:663–676. 2006. View Article : Google Scholar : PubMed/NCBI
40	Hockemeyer D, Soldner F, Beard C, et al: Efficient targeting of expressed and silent genes in human ESCs and iPSCs using zinc-finger nucleases. Nat Biotechnol. 27:851–857. 2009. View Article : Google Scholar : PubMed/NCBI
41	Zou J, Maeder ML, Mali P, et al: Gene targeting of a disease-related gene in human induced pluripotent stem and embryonic stem cells. Cell Stem Cell. 5:97–110. 2009. View Article : Google Scholar : PubMed/NCBI
42	Itzhaki I, Maizels L, Huber I, et al: Modelling the long QT syndrome with induced pluripotent stem cells. Nature. 471:225–229. 2011. View Article : Google Scholar : PubMed/NCBI
43	Malan D, Friedrichs S, Fleischmann BK and Sasse P: Cardiomyocytes obtained from induced pluripotent stem cells with long-QT syndrome 3 recapitulate typical disease-specific features in vitro. Circ Res. 109:841–847. 2011. View Article : Google Scholar : PubMed/NCBI
44	Moretti A, Bellin M, Welling A, et al: Patient-specific induced pluripotent stem-cell models for long-QT Syndrome. N Engl J Med. 363:1397–1409. 2010. View Article : Google Scholar : PubMed/NCBI
45	Leonard JN and Schaffer DV: Antiviral RNAi therapy: Emerging approaches for hitting a moving target. Gene Ther. 13:532–540. 2006. View Article : Google Scholar : PubMed/NCBI
46	Boudreau RL, Spengler RM and Davidson BL: Rational design of therapeutic siRNAs: Minimizing off-targeting potential to improve the safety of RNAi therapy for Huntington's disease. Mol Ther. 19:2169–2177. 2011. View Article : Google Scholar : PubMed/NCBI